A one-year prospective,randomized,placebo-controlled,quadruple-blinded,phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)
Free accessOtherFirst published online January, 2010
A one-year prospective,randomized,placebo-controlled,quadruple-blinded,phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)
Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages.
Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple sclerosis (MS).
Methods: Twenty-four treatment-naïve R—RMS patients participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every patient injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1 : 1) to either active oral MMF or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events.
Results: In this small pilot investigation, no differences were identified between the two treatment groups with respect to patient-reported adverse events, MRI metrics, or laboratory abnormalities. Notwithstanding these observations, and the limited number of patients treated, trends appeared to favor the combination therapy regimen.
Conclusions: The combination treatment regimen of interferon beta-1a and MMF appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted.
Aharoni, R., Kayhan, B., Eilam, R., Sela, M. and Arnon, R. ( 2003) Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA100: 14157-14162.
2.
Ameen, M., Smith, H.R. and Barker, J.N. ( 2001) Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol26: 480-483.
3.
Barten, M.J., van Gelder, T., Gummert, J.F., Boeke, K., Shorthouse, R., Billingham, M.E. et al. (2002a) Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant2: 719-732.
4.
Barten, M.J., van Gelder, T., Gummert, J.F., Shorthouse, R., Morris, R.E. et al. (2002b) Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol10: 1-14.
5.
Berger, J.R. and Houff, S.(2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol65: 367-377.
6.
Boster, A., Edan, G., Frohman, E., Hauser, S., Javed, A., Stuve, O. et al. (2008) Intense immunosuppression in rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology7: 173-183.
7.
Chaudhry, V., Cornblath, D.R., Griffin, J.W., O’Brien, R., Drachman, D.B. et al. (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology56: 94-96.
8.
Ciafaloni, E., Massey, J.M., Tucker-Lipscomp, B. and Sanders, D.B. ( 2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology56: 97-99.
9.
Cohen, J.A., Imrey, P.B., Calabresi, P.A., Edwards, K.R., Eickenhorst, T., Felton WL 3rd. et al. (2009) Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology72: 535-541.
10.
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O. et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357: 1576-1582.
11.
Daina, E., Schieppati, A. and Remuzzi, G. ( 1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med130: 422-426.
12.
Filippi, M., Bozzali, M., Rovaris, M., Gonen, O., Kesavadas, C., Ghezzi, A. et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain126: 433-437.
13.
Frohman, E.M., Filippi, M., Stüve, O., Waxman, S.G., Corboy, J., Phillips, J.T. et al. (2005a) Characterizing the mechanisms of progression in multiple sclerosis. Arch Neurol62: 1345-1356.
14.
Frohman, E.M., Stüve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R. et al. (2005b) Therapeutic considerations for disease progression in multiple sclerosis. Arch Neurol62: 1519-1530.
15.
Frohman, E.M., Brannon, K., Racke, M.K. and Hawker, K. ( 2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol27: 80-83.
16.
Frohman, E.M., Raine, C. and Racke, M.K. ( 2006) Multiple sclerosis: the plaque and its pathogenesis. New Engl J Med354: 942-955.
17.
Gelber, A.C., Nousari, H.C. and Wigley, F.M. ( 2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol27: 1542-1545.
18.
Goodin, D., Frohman, E.M., Garmany, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis . Neurology58: 169-178.
19.
Gorson, K.C., Amato, A.A. and Ropper, A.H. ( 2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology63: 715-717.
20.
Hauser, R.A., Malek, A.R. and Rosen, R. ( 1998) Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology51: 912-913.
21.
Hong, J., Li, N., Zhang, X., Zheng, B. and Zhang, J.Z. ( 2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA102: 6449-6454.
22.
Ishida, H., Tanabe, K., Furusawa, M., Ishizuka, T., Shimmura, H., Tokumoto, T. et al. (2002) Mycophenolate mofetil suppresses the production of anti-blood type antibodies after renal transplantation across the blood brain barrier: ELISA to detect humoral activity. Transplantation74: 1187-1189.
23.
Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med343: 898-904.
24.
Jonsson, C. and Carlsten, H. ( 2002) Mycophenolic acid inhibits inosine 5 (') monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol216: 93-101.
25.
Kappos, L., Polman, C.H., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67: 1242-1249.
26.
Karandikar, N.J., Crawford, M.P., Yan, X., Ratts, R.B., Brenchley, J.M., Ambrozak, D.R. et al. (2002) Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest109: 641-649.
27.
Karim, M.Y., Alba, P., Cuadrado, M.J., Abbs, I.C., D’Cruz, D.P., Khamashta, M.A. et al. (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology, Oxford41: 876-882.
28.
Kieseier, B., Wiendl, H., Hartung, H.P., Stuve, O. et al. (2009) The future of multiple sclerosis therapy. Pharmacological Research60: 207-211.
29.
Kinkel, R.P., Kollman, C., O’Connor, P., Murray, T.J., Simon, J., Arnold, D. et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology66: 678-684.
30.
Lui, S.L., Tsang, R., Wong, D., Chan, K.W., Chan, T.M., Fung, P.C. et al. (2002) Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus11: 411-418.
31.
Mowzoon, N., Sussman, A. and Bradley, W.G. ( 2001) Mycophenolate (Cellcept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci185: 119-122.
32.
Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. ( 2000) Medical progress: multiple sclerosis. N Engl J Med343: 938-952.
33.
O’Connor, P.W., Li, D., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66: 894-900.
34.
Polman, C.H., O’Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med354: 899-910.
35.
Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol58: 840-846.
36.
Quemeneur, L., Flacher, M., Gerland, L.M., Ffrench, M., Revillard, J.P., Bonnefoy-Berard, N. et al. (2002) Mycophenolic acid inhibits IL-2 dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis . J Immunol169: 2747-2755.
37.
Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med354: 911-923.
38.
Schanz, S., Ulmer, A., Rassner, G. and Fierlbeck, G. ( 2002) Successful treatment of subacute cutaneous lupus erythematosis with mycophenolate mofetil. Br J Dermatol147: 174-178.
39.
Schneider, C., Gold, R., Reiners, K. and Toyka, K.V. ( 2001) Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol46: 79-82.
40.
Schneider, C., Gold, R., Schafers, M. and Toyka, K.V. ( 2002) Mycophenolate mofetil in the therapy of poly-myositis associated with a polyautoimmune syndrome. Muscle Nerve25: 286-288.
41.
Schrader, P., Mooser, G., Peter, R.U. and Puhl, W. ( 2002) Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil. Z Rheumatol61: 545-550.
42.
Smith, S.M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P.M., Federico, A. et al. (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage17: 479-489.
43.
Stuve, O., Dooley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G. et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol40: 853-863.
44.
Tennakoon, D.K., Mehta, R.S., Ortega, S.B., Bhoj, V., Racke, M.K. and Karandikar, N.J. ( 2006) Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol176: 7119-7129.
45.
Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J. et al. (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol256: 568-576.
46.
Waiser, J., Budde, K., Braasch, E. and Neumayer, H.H. ( 1999) Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis34: e9.
47.
Weiner, H.L. ( 2008) A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol255 (Suppl. 1): 3-11.
48.
Weiner, H.L. ( 2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?Ann Neurol65: 239-248.
49.
Zivadinov, R., Reder, A.T., Filippi, M., Minagar, A., Stuve, O., Lassman, H. et al. (2008) Mechanisms of action of disease modifying therapy in MS: the relationship of the dynamics of short and long term changes in brain volume. Neurology71: 136-144.
